Profusa Inc. (PFSA) Stock: Drops as G3 Deal Hinges on $30M Financing
TLDRProfusa stock drops after hours as the G3 acquisition faces key conditions.The G3 deal requires at least $30 million in secured financing before completion.G3s unaudited 2025 revenue estimate of $111 million supports the deal value.Shareholder approval is needed to convert preferred stock into common shares.Profusa must retain its Nasdaq listing and resolve G3 debt before the closing. Profusa shares closed unchanged at $1.06 in regular trading before dropping 3.77% to $1.02 during after-hours trading. The decline followed a formal option agreement covering Profusas proposed acquisition of G3 Vision Labs and three subsidiaries. The transaction now depends on financing, debt restructuring, shareholder approval, and continued Nasdaq listing compliance for the proposed transaction. Profusa, Inc. Common Stock, PFSA Profusa Sets Terms for G3 Acquisition Profusa secured the right to acquire G3 Vision Labs, Med Screen Laboratories, Dominion Diagnostics, and Acutis Diagnostics under the agreement. The option remains open until G3 provides required financial records, followed by an additional 90-day exercise period under agreed terms. G3 estimated 2025 net revenue at about $111 million using unaudited management information for the diagnostics group and subsidiaries. The proposed combination would create a public diagnostics company operating national laboratories certified under federal CLIA standards across several markets. These laboratories serve addiction